

## **IN THE CLAIMS**

1. (currently amended) An immunogenic composition comprising a GBS saccharide antigen and at least two GBS polypeptide antigens, wherein said GBS saccharide antigen comprises a saccharide selected from GBS serotype Ia, Ib, and III, and wherein said GBS polypeptide antigens comprise a combination of at least two polypeptide or fragments thereof selected from the antigen group consisting of GBS 80 as represented by SEQ ID NO:2, GBS 91 as represented by SEQ ID NO:4, GBS 104 as represented by SEQ ID NO:6, GBS 147 as represented by SEQ ID NO:8, GBS 173 as represented by SEQ ID NO:10, GBS 276 as represented by SEQ ID NO:12, GBS 305 as represented by SEQ ID NO:14, GBS 313 as represented by SEQ ID NO:16, GBS 322 as represented by SEQ ID NO:18, GBS 328 as represented by SEQ ID NO:20, GBS 330 as represented by SEQ ID NO:22, GBS 338 as represented by SEQ ID NO:24, GBS 358 as represented by SEQ ID NO:26, GBS 361 as represented by SEQ ID NO:28, GBS 404 as represented by SEQ ID NO:30, GBS 656 as represented by SEQ ID NO:32, GBS 690 as represented by SEQ ID NO:34, and GBS 691 as represented by SEQ ID NO:36.

2. (original) The immunogenic composition of claim 1, wherein said GBS polypeptide antigens further comprise a GBS polypeptide or a fragment thereof of serogroup II.

3. (currently amended) The immunogenic composition of claim 1, wherein said GBS polypeptide antigen combination comprises GBS 80 as represented by SEQ ID NO:2 or a fragment thereof.

4. (currently amended) The immunogenic composition of claim 3, wherein said GBS polypeptide antigens comprise a combination of two GBS antigens or fragments thereof selected from the group consisting of (1) GBS 80 as represented by SEQ ID NO:2 and GBS 91 as

represented by SEQ ID NO:4, (2) GBS 80 as represented by SEQ ID NO:2 and GBS 104 as represented by SEQ ID NO:6, (3) GBS 80 as represented by SEQ ID NO:2 and GBS 147 as represented by SEQ ID NO:8, (4) GBS 80 as represented by SEQ ID NO:2 and GBS 173 as represented by SEQ ID NO:10, (5) GBS 80 as represented by SEQ ID NO:2 and GBS 276 as represented by SEQ ID NO:12, (6) GBS 80 as represented by SEQ ID NO:2 and GBS 305 as represented by SEQ ID NO:14, (7) GBS 80 as represented by SEQ ID NO:2 and GBS 313 as represented by SEQ ID NO:16, (8) GBS 80 as represented by SEQ ID NO:2 and GBS 322 as represented by SEQ ID NO:18, (9) GBS 80 as represented by SEQ ID NO:2 and GBS 328 as represented by SEQ ID NO:20, (10) GBS 80 as represented by SEQ ID NO:2 and GBS 330 as represented by SEQ ID NO:22, (11) GBS 80 as represented by SEQ ID NO:2 and GBS 338 as represented by SEQ ID NO:24, (12) GBS 80 as represented by SEQ ID NO:2 and GBS 358 as represented by SEQ ID NO:26, (13) GBS 80 as represented by SEQ ID NO:2 and GBS 361 as represented by SEQ ID NO:28, (14) ~~GBS 80 and GBS 404~~, (14) GBS 80 as represented by SEQ ID NO:2 and GBS 404 as represented by SEQ ID NO:30, (15) GBS 80 as represented by SEQ ID NO:2 and GBS 656 as represented by SEQ ID NO:32, (16) GBS 80 as represented by SEQ ID NO:2 and GBS 690 as represented by SEQ ID NO:34, and (17) GBS 80 as represented by SEQ ID NO:2 and GBS 691 as represented by SEQ ID NO:36.

5. (currently amended) The immunogenic composition of claim 4, wherein said combination is selected from the group consisting of (1) GBS 80 as represented by SEQ ID NO:2 and GBS 338 as represented by SEQ ID NO:24; (2) GBS 80 as represented by SEQ ID NO:2 and GBS 361 as represented by SEQ ID NO:28, (3) GBS 80 as represented by SEQ ID NO:2 and GBS 305 as represented by SEQ ID NO:14, (4) GBS 80 as represented by SEQ ID NO:2 and GBS 328 as represented by SEQ ID NO:20, (5) GBS 80 as represented by SEQ ID NO:2 and

GBS 690 as represented by SEQ ID NO:34, (6) GBS 80 as represented by SEQ ID NO:2 and GBS 691 as represented by SEQ ID NO:36, and (7) GBS 80 as represented by SEQ ID NO:2 and GBS 147 as represented by SEQ ID NO:8.

6. (currently amended) The immunogenic composition of claim 4, wherein said combination comprises GBS 80 as represented by SEQ ID NO:2 and GBS 691 as represented by SEQ ID NO:36.

7. (original) The immunogenic composition of claim 1, wherein said composition comprises a combination of at least three GBS polypeptide antigens.

8. (currently amended) The immunogenic composition of claim 7, wherein said combination comprises GBS 80 as represented by SEQ ID NO:2 and GBS691 as represented by SEQ ID NO:36.

9. (currently amended) The immunogenic composition of claim 7, wherein said combination comprises GBS 80 as represented by SEQ ID NO:2.

10. (original) The immunogenic composition of claim 1, wherein at least one GBS polypeptide antigen is covalently linked to the GBS saccharide antigen.

11. (original) The immunogenic composition of claim 1, wherein said GBS saccharide antigen is covalently linked to a carrier protein.

12. (original) The immunogenic composition of claim 11, wherein said carrier protein is selected from the group consisting of tetanus toxoid, diphtheria toxoid, *N. meningitides* outer membrane protein, heat shock protein, pertusis protein, protein D from *H. influenzae*, and toxin A or B from *C. difficile*.

13. (original) The immunogenic composition of claim 12, wherein said carrier protein is selected from the group consisting of tetanus toxoid and diphtheria toxoid.

14. (original) The immunogenic composition of claim 13, wherein said carrier protein is a diphtheria toxoid.

15. (original) The immunogenic composition of claim 14, wherein said diphtheria toxoid is CRM197.

16. (original) A method for the therapeutic or prophylactic treatment of GBS infection in an animal susceptible to GBS infection comprising administering to said animal a therapeutic or prophylactic amount of the immunogenic composition of claim 1.

17. (currently amended) A method for the manufacture of a medicament for raising an immune response against GBS comprising combining a GBS saccharide antigen and at least two GBS polypeptide antigens, wherein said GBS saccharide antigen comprises a saccharide selected from GBS serotype Ia, Ib, and III, and wherein said GBS polypeptide antigens comprise a combination of at least two polypeptide or fragments thereof selected from the antigen group consisting of GBS 80 as represented by SEQ ID NO:2, GBS 91 as represented by SEQ ID NO:4, GBS 104 as represented by SEQ ID NO:6, GBS 147 as represented by SEQ ID NO:8, GBS 173 as represented by SEQ ID NO:10, GBS 276 as represented by SEQ ID NO:12, GBS 305 as represented by SEQ ID NO:14, GBS 313 as represented by SEQ ID NO:16, GBS 322 as represented by SEQ ID NO:18, GBS 328 as represented by SEQ ID NO:20, GBS 330 as represented by SEQ ID NO:22, GBS 338 as represented by SEQ ID NO:24, GBS 358 as represented by SEQ ID NO:26, GBS 361 as represented by SEQ ID NO:28, GBS 404 as represented by SEQ ID NO:30, GBS 656 as represented by SEQ ID NO:32, GBS 690 as represented by SEQ ID NO:34, and GBS 691 as represented by SEQ ID NO:36.

18. (new) The immunogenic composition of claim 1, wherein the two GBS polypeptide antigens are GBS 80 as represented by SEQ ID NO:2 and GBS 322 as represented by SEQ ID NO:18.

19. (new) The immunogenic composition of claim 18 wherein the GBS saccharide antigen comprises the GBS serotype Ia saccharide.

20. (new) The immunogenic composition of claim 18 further comprising a diphtheria toxoid.

21. (new) The immunogenic composition of claim 20 wherein the diphtheria toxoid is CRM197.

22. (new) The immunogenic composition of claim 19 further comprising a diphtheria toxoid.

23. (new) The immunogenic composition of claim 22 wherein the diphtheria toxoid is CRM197.